Lilly stockpiles about $550 million of experimental weight-loss pill orforglipron

Eli Lilly recorded nearly $550 million in "pre-launch inventory" for orforglipron, its experimental oral weight-loss pill, according to financial statements filed on Feb. 19, 2025 ^[1]. The company built that stockpile more than a year before the drug is expected to reach the market ^[1]. A separate report put the inventory figure at $548 million and said the stockpile consists of soon-to-be-launched drugs and related materials, primarily orforglipron ^[2].

Drugmakers usually record pre-launch inventory shortly before a product is approved, to show how much has been manufactured ahead of a launch ^[1]. Lilly's filing came well before that point. "There have been recent similar pre-launch inventory builds, especially around COVID-19 vaccines, but with the launch not coming until 2026, this earlier-than-normal inventory build is certainly much larger than normal," said Kevin Gade, chief operating officer at Bahl & Gaynor, which owns Lilly shares ^[1]. Gade said the build reflects Lilly's wish to launch the drug as early as possible and gain a time advantage against future competition ^[1].

Umer Raffat, an analyst at Evercore ISI, flagged the inventory in a research note and said the capitalized amount implied $10 billion in sales based on 2024 figures alone. Raffat added that the build-up will inevitably grow ^[1].

Orforglipron is not approved. In a mid-stage trial, the highest dose led to 14.7% weight loss after 36 weeks for people who were obese or overweight ^[1]. Lilly is expected to report late-stage trial data by April ^[1]. On a conference call this month, the company said it was already building manufacturing capacity for the drug ^[1]. Lilly and Novo Nordisk currently dominate the weight-loss market with injectable drugs; Novo is studying a pill version of its experimental drug amycretin, and other companies including AstraZeneca are also developing oral obesity treatments ^[1].

Why it matters for patients

The practical question for patients is what a stockpile this size means for supply if and when the pill is cleared for sale. Manufacturing ahead of a launch can shorten the gap between approval and shipping, but the reports do not say that Lilly has committed to any specific supply level, launch date or price.

Nothing in these reports establishes whether orforglipron will be approved, what it would cost, or whether insurers and pharmacy benefit managers would cover it. Lilly has not disclosed a launch date, and the timeline described by an investor who follows the company points to 2026 ^[1]. Approval itself has not been reported.

The mid-stage result — 14.7% weight loss at 36 weeks at the highest dose — comes from a smaller study and is not proof of how the drug will perform in the larger late-stage trial now being analyzed ^[1]. Patients weighing oral against injectable options do not yet have that late-stage evidence.

What happens next

Lilly is expected to report late-stage data for orforglipron by April ^[1]. The inventory on Lilly's books grew from a filing reported in February 2025 and, according to one analyst, is expected to keep growing ^[1]. The company has said it is building manufacturing capacity now ^[1]. Whether regulators clear the pill, and on what timeline, has not been reported.